| Beta-blockers and inspiratory pulmonary function in chronic heart failure. | |
| | |
MedLine Citation:
|
PMID: 15732030 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Chronic heart failure (CHF) patients complain of breathlessness and fatigue. Respiratory muscle function is impaired in CHF patients and may contribute to their symptoms. Beta-blockers cause fatigue but have become part of the standard management of CHF. We explored the relation between respiratory muscle power in CHF and the effects of long-term beta-blockade. METHODS AND RESULTS: A total of 52 CHF patients and 25 control subjects underwent echocardiography, peak exercise testing with metabolic gas exchange analysis, and measurement of forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), peak inspiratory flow (PIF), and forced inspiratory volume in 1 second (FIV1). Of the patients, 35 started beta-blocker therapy and were tested again at 1 year. Patients had lower peak oxygen consumption (pV(O2) (19.3 [4.5] versus 37.3 [8.4] mL/kg/min, P < .0001), exercise time (414 [134] versus 817 [193] seconds, P < .0001), and anaerobic threshold (13.8 [3.8] versus 27.2 [8.2] mL/kg/min, P < .0001). Patients also had a steeper relationship between ventilation (V(E)) and carbon dioxide (CO2 ) (V(E)/V(CO2)) (40.0 [6.8] versus 26.4 [2.0], P < .0001); lower FEV1, FVC, and FIV1 (89 [15] versus 111 [24]% expected, P < .0001, 80 [20] versus 94 [21]% expected, P < .001 and 2.5 [1.6] versus 3.0 (0.9) L, P < .02); and there was a correlation between pV(O2) and FIV1 (r = 0.24, P < .05) for the patients. The slope relating symptoms of breathlessness (Borg score) to ventilation (Borg/V(E) slope) also correlated with FIV1 (r = 0.36, P < .02). Beta-blocker therapy improved echocardiographic variables, but not pV(O2). There was no change in PIF or FIV1. There was a significant reduction in FEV 1 after beta-blocker treatment (P < .01). CONCLUSION: Inspiratory flows are impaired in patients with chronic heart failure and correlate with the degree of functional impairment. This may be due to a combination of respiratory muscle weakness and reduced lung compliance. The reduction in inspiratory capacity is not influenced by long-term beta-blockade. |
| | |
Authors:
|
Klaus K A Witte; Andrew L Clark |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Journal of cardiac failure Volume: 11 ISSN: 1071-9164 ISO Abbreviation: J. Card. Fail. Publication Date: 2005 Mar |
Date Detail:
|
Created Date: 2005-02-25 Completed Date: 2005-07-11 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9442138 Medline TA: J Card Fail Country: United States |
Other Details:
|
Languages: eng Pagination: 112-6 Citation Subset: IM |
Affiliation:
|
Academic Cardiology, Castle Hill Hospital, Cottingham, Hull, England. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adrenergic beta-Antagonists
/
therapeutic use* Aged Case-Control Studies Echocardiography Exercise Test Heart Failure / drug therapy*, physiopathology* Humans Inspiratory Capacity / drug effects Pulmonary Gas Exchange Respiratory Function Tests Respiratory Muscles / drug effects*, physiopathology* Spirometry Time Factors |
| Chemical | |
Reg. No./Substance:
|
0/Adrenergic beta-Antagonists |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Managed care patients with heart failure: spectrum of ventricular dysfunction and predictors of medi...
Next Document: Relationship between oxidative stress and systolic dysfunction in patients with hypertrophic cardiom...